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Introduction
Conclusions
References
Fulminant hepatic failure (also called acute hepatic failure) is a disease 
characterized with acute liver injury, hepatic encephalopathy and elevated 
prothrombic time/ international normalized ratio (INR). It has a dismal prognosis 
if left untreated and mandated early clinical intervention and potential liver 
transplantation in some cases. Among the most common etiologies are infection 
(e.g. Viral hepatitis), and drug induced (e.g. Acetaminophen). Drug induced liver 
injury (DILI) is the most common cause of acute liver injury in the United States 
with higher incidence in women. It can come with various clinical presentation 
including hepatocellular, cholestatic and mixed ones. Terbinafine is a drug used to 
treat skin and nails superficial fungal infections. DILI following terbinafine 
present clinically with hypersensitivity signs including rash, fever and 
eosinophilia. Here we are presenting a case of a patient with fulminant hepatic 
failure with patient death. 
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Case Report
A 72 year-old-patient without known past medical history presented to the hospital with 
worsening cough, dyspnea on exertion, decreased appetite, weight loss for two months. 
Prior to admission, he was treated with a 10- day course of levofloxacin and prednisone 
as a case of bronchitis with minimal improvement. Then he started to develop red urine 
with marked changes in mental status. On physical examination, the patient had notifiable 
scleral icterus, confusion and abdominal tenderness in the right upper quadrant. 
On admission his labs were significant for alkaline phosphatase 541, aspartate 
transaminase 557, alanine transaminase 94, total bilirubin 8.6, lactate 11.7.
CT scan of abdomen showed hepatosplenomegaly, mild ascites and trace bilateral pleural 
effusion. Work up with Viral hepatitis serology, cryptococcal antigen, histoplasma 
antigen, respiratory virus panel, Epstein Barr virus tests were negative. Anti-nuclear 
antibodies (ANA) and anti-mitochondrial antibody were also negative. Blood level of 
amylase, lipase, acetaminophen and alcohol were negative at admission too. The patient 
was started initially on broad spectrum antibiotics, N-acetyl cysteine empirically and 
aggressive intravenous fluid hydration.  Patient condition rapidly worsened and he 
developed profound shock requiring mechanical ventilation and started on stress dose 
steroid and pressor support. Upon further investigation, patient was noted to take 
terbinafine for toe onychomycosis (day 112).  Ferritin level was elevated to 1596 with 
93% iron saturation. Ceruloplasmin level was normal. Patient was not a transplant 
candidate due to multiple organ failure. As per family request, patient was palliatively 
extubated and died. 
Discussion
Terbinafine is a fungicidal drug with activity against dermatophytes 
including Epidermophyton flccosum and trichophyton rubrum. It 
works by inhibition of squalene epoxidase with a resultant 
accumulation of squalene in the fungal cell and killing it as a result. 
Commonly used orally to treat onychomycosis and other fingernails 
and toenails infections. Shortly after its introduction to the market, 
DILI had been reported with elevation with serum aminotransferases 
elevation that was usually self-limited. Usually presents within first 6 
weeks of therapy with either hepatocellular or cholestatic initially with 
sings of hypersensitivity. Mechanism of injury entails hypersensitivity 
reaction, though the full pathogenesis was not elucidated yet, but 
genetic polymorphism is implicated in the variable presentation 
especially among HLA-A 33:01 allele carriers. Terbinafine DILI 
resolves usually within 6 months of stopping the medication but can 
lead to death or need liver transplantation in some cases. 
Figure 1: Acute liver failure from DILI. Most of the
parenchyma has been destroyed and collapsed
(confluent necrosis) with only a few viable
hepatocytes remaining. There is a mild infiltrate of
inflammatory cells in the areas of necrosis. Arrows
point to ceroid-containing macrophages. Source:
Uptodate.com
Figure 2: Medications associated with acute liver
failure. Source: uptodate.com
DILI is among the most common causes of DILI in the USA and high 
index of suspicion should be followed when cholestatic features or liver 
enzymes level start to elevate. Terbinafine DILI is usually self-limited and 
resolves with minimal sequel but in our case, the patient developed 
fulminant hepatic failure and died in a short course. Antifungals can be 
lifesaving but with dangerous side effect profile sometimes. The presence 
of hemochromatosis in this patient predisposed him to mortality. 
